How to Indicate Implantable Cardioverter-Defibrillator in Patients With Malignancy.
作者信息
Kataoka Naoya, Imamura Teruhiko
机构信息
Second Department of Internal Medicine University of Toyama Toyama Japan.
出版信息
J Arrhythm. 2025 Jul 16;41(4):e70148. doi: 10.1002/joa3.70148. eCollection 2025 Aug.
Abstract
摘要
相似文献
1
How to Indicate Implantable Cardioverter-Defibrillator in Patients With Malignancy.
J Arrhythm. 2025 Jul 16;41(4):e70148. doi: 10.1002/joa3.70148. eCollection 2025 Aug.
2
Sex-Related Differences in Ventricular Tachyarrhythmia Events in Patients With Implantable Cardioverter-Defibrillator and Prior Ventricular Tachyarrhythmias.
JACC Clin Electrophysiol. 2024 Feb;10(2):284-294. doi: 10.1016/j.jacep.2023.09.028. Epub 2023 Nov 29.
3
Prognostic comparison between implantable cardioverter-defibrillator and amiodarone in cancer patients.
J Arrhythm. 2025 May 19;41(3):e70093. doi: 10.1002/joa3.70093. eCollection 2025 Jun.
4
Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials.
Heart Rhythm. 2016 Jul;13(7):1552-9. doi: 10.1016/j.hrthm.2016.03.004. Epub 2016 Mar 4.
5
Patients' perception of implantable cardioverter defibrillator deactivation at the end of life.
Palliat Med. 2015 Apr;29(4):310-23. doi: 10.1177/0269216314550374. Epub 2014 Sep 19.
6
Incidence and Predictors of Appropriate Implantable Cardioverter Defibrillator Therapy in Japanese Ischemic Heart Disease Patients.
Circ J. 2025 Feb 25;89(3):354-363. doi: 10.1253/circj.CJ-24-0436. Epub 2024 Oct 11.
7
Rescue from sudden ventricular tachycardia and fibrillation using wearable cardioverter-defibrillator in male late-onset Fabry disease patient.
J Cardiol Cases. 2024 Dec 6;31(2):53-56. doi: 10.1016/j.jccase.2024.11.004. eCollection 2025 Feb.
8
Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials.
BMJ. 2007 Nov 3;335(7626):925. doi: 10.1136/bmj.39343.511389.BE. Epub 2007 Oct 11.
9
Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme.
Arch Cardiovasc Dis. 2025 Mar;118(3):178-184. doi: 10.1016/j.acvd.2024.10.335. Epub 2025 Jan 23.
10
Patients, intimate partners and family experiences of implantable cardioverter defibrillators: qualitative systematic review.
J Adv Nurs. 2011 Dec;67(12):2537-50. doi: 10.1111/j.1365-2648.2011.05694.x. Epub 2011 May 25.
本文引用的文献
1
Prognostic comparison between implantable cardioverter-defibrillator and amiodarone in cancer patients.
J Arrhythm. 2025 May 19;41(3):e70093. doi: 10.1002/joa3.70093. eCollection 2025 Jun.
2
How to indicate implantable cardioverter-defibrillator in the aging population.
J Arrhythm. 2025 Mar 13;41(2):e70038. doi: 10.1002/joa3.70038. eCollection 2025 Apr.
3
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Front Immunol. 2024 Feb 5;15:1340373. doi: 10.3389/fimmu.2024.1340373. eCollection 2024.
4
JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias.
Circ J. 2021 Jun 25;85(7):1104-1244. doi: 10.1253/circj.CJ-20-0637. Epub 2021 Jun 1.
5
Rate control in atrial fibrillation.
Lancet. 2016 Aug 20;388(10046):818-28. doi: 10.1016/S0140-6736(16)31258-2.
Zotero 插件